Targeting Polymerase Theta (POLθ) for Cancer Therapy

Area of Science:

• Molecular Biology
• Genetics
• Oncology

Background:

• Polymerase theta (POLθ) is a crucial enzyme in microhomology-mediated end-joining (MMEJ) DNA repair.
• POLθ is overexpressed in various cancers, particularly those deficient in DNA repair pathways.
• This overexpression creates a vulnerability, making cancer cells sensitive to POLθ inhibition via synthetic lethality.

Approach:

• Review of the mechanism of POLθ-mediated MMEJ.
• Analysis of current strategies for developing POLθ inhibitors targeting its helicase or polymerase domains.
• Exploration of the clinical applications of POLθ inhibitors in cancer therapy.

Key Points:

• POLθ's central role in MMEJ DNA repair.
• The link between POLθ overexpression and cancer susceptibility.
• The development of POLθ inhibitors as a targeted cancer therapy approach.
• Potential clinical utility of POLθ inhibitors in treating specific cancer types.

Conclusions:

• POLθ is a validated therapeutic target in oncology.
• Inhibitors targeting POLθ are advancing through clinical trials.
• Targeting POLθ represents a promising strategy for synthetic lethality in cancer treatment.